Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 2/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.42 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.42 |
| ▸ | PI4KA | P42356 | 1/20 | 0.42 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.42 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.41 |
| ▸ | HBB | P68871 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.40 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15942810 | 0.80 | CYP1A2 (0.44) | PIK3CAPIK3CDPIP5K1CPIK3CBPI4KA | |
| SCHEMBL622678 | 0.80 | PDGFRB (0.48) | KDM4EALDH1A1MEN1KMT2APDGFRB | |
| SCHEMBL30891066 | 0.79 | TLR9 (0.50) | PIK3CAPIK3CDPIP5K1CPIK3CBPI4KA | |
| SCHEMBL622060 | 0.79 | PDGFRB (0.40) | PIK3CAPIK3CDPIP5K1CPIK3CBPI4KA | |
| SCHEMBL3566631 | 0.79 | TLR9 (0.50) | PIK3CAPIK3CDPIP5K1CPIK3CBPI4KA | |
| SCHEMBL25113003 | 0.79 | EGFR (0.41) | PIK3CAPIK3CDPIP5K1CPIK3CBPI4KA | |
| SCHEMBL622358 | 0.79 | HPGD (0.41) | PIK3CAPIK3CDPIP5K1CPIK3CBPI4KA | |
| SCHEMBL17244314 | 0.79 | PDGFRB (0.40) | PIK3CAPIK3CDPIP5K1CPIK3CBPI4KA | |
| SCHEMBL2493324 | 0.79 | PDGFRB (0.40) | PIK3CAPIK3CDPIP5K1CPIK3CBPI4KA | |
| SCHEMBL13554346 | 0.76 | CSF1R (0.41) | PIK3CAPIK3CDPIP5K1CPIK3CBPI4KA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109698-A1 | MALT-1 MODULATORS | EXSCIENTIA AI LIMITED (GB) | 2026-04-23 | — | — | US | disclosed |
| US-20250051327-A1 | MALT-1 MODULATORS | RECURSION PHARMACEUTICALS, INC. | 2025-02-13 | — | — | US | disclosed |
| US-20150336954-A1 | Process for Manufacturing a Naphthyridine Derivative | ACTELION PHARMACEUTICALS LTD (CH) | 2015-11-26 | — | — | US | disclosed |
| US-20150336954-A1 | Process for Manufacturing a Naphthyridine Derivative | ACTELION PHARMACEUTICALS LTD (CH) | 2015-11-26 | — | — | US | disclosed |
| US-20150336954-A1 | Process for Manufacturing a Naphthyridine Derivative | ACTELION PHARMACEUTICALS LTD (CH) | 2015-11-26 | — | — | US | disclosed |
| US-9133219-B2 | Bicyclic antibiotics | BASILEA PHARMACEUTICA AG (CH) | 2015-09-15 | — | — | US | disclosed |
| US-9127002-B2 | Process for manufacturing a naphthyridine derivative | ACTELION PHARMACEUTICALS LTD (CH) | 2015-09-08 | — | — | US | disclosed |
| US-9127002-B2 | Process for manufacturing a naphthyridine derivative | ACTELION PHARMACEUTICALS LTD (CH) | 2015-09-08 | — | — | US | disclosed |
| US-9127002-B2 | Process for manufacturing a naphthyridine derivative | ACTELION PHARMACEUTICALS LTD (CH) | 2015-09-08 | — | — | US | disclosed |
| US-20150080373-A1 | NOVEL BICYCLIC ANTIBIOTICS | Basiliea Pharmaceutica AG | 2015-03-19 | — | — | US | disclosed |
| US-20150025244-A1 | Process for Manufacturing a Naphthyridine Derivative | Acteon Pharmaceuticals Ltd. (CH) | 2015-01-22 | — | — | US | disclosed |
| US-8927542-B2 | Bicyclic antibiotics | BASILEA PHARMACEUTICA AG (CH) | 2015-01-06 | — | — | US | disclosed |
| EP-2812334-A1 | PROCESS FOR MANUFACTURING A NAPHTHYRIDINE DERIVATIVE | Actelion Pharmaceuticals Ltd. (CH) | 2014-12-17 | — | — | EP | disclosed |
| US-20140221348-A1 | NOVEL BICYCLIC ANTIBIOTICS | BASILEA PHARMACEUTICA AG (CH) | 2014-08-07 | — | — | US | disclosed |
| CN-103827665-A | Peptide deformylase inhibitors | GLAXOSMITHKLINE LLC | 2014-05-28 | — | — | CN | disclosed |
| US-8716280-B2 | Bicyclic antibiotics | BASILEA PHARMACEUTICA AG (CH) | 2014-05-06 | — | — | US | disclosed |
| EP-2684039-A2 | PEPTIDE DEFORMYLASE INHIBITORS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2014-01-15 | — | — | EP | disclosed |
| WO-2013118086-A1 | PROCESS FOR MANUFACTURING A NAPHTHYRIDINE DERIVATIVE | ACTELION PHARMACEUTICALS LTD (CH) | 2013-08-15 | — | — | WO | disclosed |
| WO-2012122450-A2 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2012-09-13 | — | — | WO | disclosed |
| US-20120040957-A1 | Novel Bicyclic Antibiotics | BASILEA PHARMACEUTICA AG | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150336954-A1 | Process for Manufacturing a Naphthyridine Derivative | NRDC, SBDS, CYP1B1 | PIK3CA 2403/4885PIK3CD 2415/4885PIP5K1C 1780/4885 |
| US-20120040957-A1 | Novel Bicyclic Antibiotics | C5, C1S, CBR3 | PIK3CA 4456/4885PIK3CD 4611/4885PIP5K1C 4272/4885 |
| US-20140221348-A1 | NOVEL BICYCLIC ANTIBIOTICS | C1S, XPA, XDH | PIK3CA 4618/4885PIK3CD 4708/4885PIP5K1C 4341/4885 |
| US-20150080373-A1 | NOVEL BICYCLIC ANTIBIOTICS | C1S, XPA, XDH | PIK3CA 4618/4885PIK3CD 4708/4885PIP5K1C 4341/4885 |
| US-20250051327-A1 | MALT-1 MODULATORS | MALT1, BCL6, BCL9 | PIK3CA 507/4885PIK3CD 313/4885PIP5K1C 2177/4885 |
| US-20260109698-A1 | MALT-1 MODULATORS | MALT1, BCL6, BCL3 | PIK3CA 2258/4885PIK3CD 1470/4885PIP5K1C 3597/4885 |
| US-20150025244-A1 | Process for Manufacturing a Naphthyridine Derivative | NRDC, SBDS, CYP1B1 | PIK3CA 2403/4885PIK3CD 2415/4885PIP5K1C 1780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.